Anti-Factor X monoclonal antibody, clone BNY-9051

2 '-hydroxyflavanone (2HF) is a dietary flavonoid with anticancer activity towards multiple cancers. Here, we report that topically applied 2HF inhibits the growth of intradermal implants of melanoma in immunocompetent mice. 2HF induced apoptosis and inhibited the growth of the human SK-MEL-24 as well as murine B16-F0 and B16-F10 melanoma cell lines in vitro. Apoptosis was associated with depletion of caspase-3, caspase-9, and PARP1 in B16-F0 and SK-MEL-24 cells. Caspase-9 and MEKK-15 were undetected even in untreated B16-F10 cells. Signaling proteins TNF alpha, and phospho-PDGFR-beta were depleted in all three cell lines; MEKK-15 was depleted by 2HF in SK-MEL-24 cells. 2HF enhanced sunitinib (an MEK and PDGFR-beta inhibitor) and AZD 2461 (a PARP1 inhibitor) cytotoxicity. 2HF also depleted the Ral-regulated, stress-responsive, antiapoptotic endocytic protein RLIP76 (RALBP1), the inhibition of which has previously been shown to inhibit B16-F0 melanoma growth in vivo. Functional inhibition of RLIP76 was evident from inhibition of epidermal growth factor (EGF) endocytosis by 2HF. We found that topically applied 2HF-Pluronic Lecithin Organogel (PLO) gel inhibited B16-F0 and B16-F10 tumors implanted in mice and caused no overt toxicity despite significant systemic absorption. 2HF treatment reduced phospho-AKT, vimentin, fibronectin, CDK4, cyclinB1, and BCL2, whereas it increased BIM and phospho-AMPK in excised tumors. Several cancer signals are controlled by endocytosis, a process strongly inhibited by RLIP76 depletion. We conclude that 2HF-PLO gel may be useful for topical therapy of cutaneous metastases of melanoma and could enhance the antineoplastic effects of sunitinib and PARP1 inhibitors. The mechanism of action of 2HF in melanoma overlaps with RLI76 inhibitors.

A series of novel 1,2,4-triazole-based schiff's base derivatives were synthesized by condensing undecenoic triazole compound with various substituted benzaldehydes. Compounds so synthesized were thoroughly characterized using H-1 nuclear magnetic resonance, C-13 nuclear magnetic resonance, high resolution mass spectrometry and Fourier transform-infrared spectroscopy. Cytotoxicity of these compounds was tested in vitro on three cancer cell lines, mouse melanoma cancer cells (B16 F10), human colon cancer cells (HCT-15), human ovarian cancer cell line (SKOV3) and normal mouse embryonic fibroblasts (NIH-3T3) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The results showed that most of the compounds exhibited cytotoxicity against the tested cell lines. Among the tested compounds, 6g and 6n showed significant cytotoxicity against B16 F10 cells and compounds 6i, 6n, 6o, 6p and 6q against HCT-15 cell line. The Schiff's base derivative 6g, appeared to be the most effective on B16 F10 cancer cells due to bromo substitution on the 4th position of the phenyl ring. Altogether, the cytotoxicity of these compounds observed against cancer cells indicate anticancer potential.